背景:物质使用障碍是世界范围内严重的公共卫生问题之一。不公平的资源,歧视,物理距离限制了患者获得医疗帮助的机会。自动化会话代理具有提供家庭和远程治疗的潜力。然而,自动对话代理大多使用文本和其他方法进行交互,影响互动体验,处理浸没,和临床疗效。
目的:本文的目的是描述Echo-APP的设计和开发,基于平板电脑的应用程序,具有虚拟数字心理治疗师的功能,并进行初步研究,探讨Echo-APP治疗甲基苯丙胺使用障碍患者的可行性和初步疗效结果。
方法:Echo-APP是由一组临床医生针对物质使用障碍(SUD)开发的评估和康复计划,心理治疗师,计算机专家。该程序可用于Android平板电脑。在评估方面,重点是SUD的核心特征,比如心情,冲动,治疗动机,和渴望水平。在治疗方面,Echo-APP提供10个治疗单位,涉及成瘾的意识,动机增强,情绪调节,冥想,等。最终共有47名甲基苯丙胺依赖患者参加了初步研究,接受了一次基于Echo-APP的动机增强治疗。在患者治疗前后评估结果,包括治疗动机,渴望水平,自我感知戒毒的重要性,以及他们停止吸毒的信心。
结果:在试点研究中,在基于Echo-APP的治疗后,改变阶段准备和治疗渴望量表的得分以及关于戒毒动机的问卷的得分显着增加(P<.001,Cohend=-0.60),而渴望减少(P=0.01,科恩d=0.38)。患者基线广泛性焦虑症-7评估评分(β=3.57;P<.001;95%CI0.80,2.89)和Barratt冲动性量表(BIS)-运动冲动性评分(β=-2.10;P=.04;95%CI-0.94,-0.02)可预测治疗期间患者治疗动机的变化。此外,患者基线广泛性焦虑症-7评估评分(β=-1.607;P=.03;95%CI-3.08,-0.14),BIS-注意冲动评分(β=-2.43;P=.004;95%CI-4.03,-0.83),和BIS非计划性冲动评分(β=2.54;P=.002;95%CI0.98,4.10)可预测治疗期间渴望评分的变化。
结论:Echo-APP是一种实用的,接受,并为甲基苯丙胺依赖患者提供有前途的虚拟数字心理治疗师计划。初步研究结果为进一步优化方案和推广SUD的大规模随机对照临床研究奠定了良好的基础。
Substance use disorder is one of the severe public health problems worldwide. Inequitable resources, discrimination, and physical distances limit patients\' access to medical help. Automated conversational agents have the potential to provide in-home and remote therapy. However, automatic dialogue agents mostly use text and other methods to interact, which affects the interaction experience, treatment immersion, and clinical efficacy.
The aim of this paper is to describe the design and development of Echo-APP, a tablet-based app with the function of a virtual digital psychotherapist, and to conduct a pilot study to explore the feasibility and preliminary efficacy results of Echo-APP for patients with methamphetamine use disorder.
Echo-APP is an assessment and rehabilitation program developed for substance use disorder (SUD) by a team of clinicians,
psychotherapists, and computer experts. The program is available for Android tablets. In terms of assessment, the focus is on the core characteristics of SUD, such as mood, impulsivity, treatment motivation, and craving level. In terms of treatment, Echo-APP provides 10 treatment units, involving awareness of addiction, motivation enhancement, emotion regulation, meditation, etc. A total of 47 patients with methamphetamine dependence were eventually enrolled in the pilot study to receive a single session of the Echo-APP-based motivational enhancement treatment. The outcomes were assessed before and after the patients\' treatment, including treatment motivation, craving levels, self-perception on the importance of drug abstinence, and their confidence in stopping the drug use.
In the pilot study, scores on the Stages of Change Readiness and Treatment Eagerness Scale and the questionnaire on motivation for abstaining from drugs significantly increased after the Echo-APP-based treatment (P<.001, Cohen d=-0.60), while craving was reduced (P=.01, Cohen d=0.38). Patients\' baseline Generalized Anxiety Disorder-7 assessment score (β=3.57; P<.001; 95% CI 0.80, 2.89) and Barratt Impulsiveness Scale (BIS)-motor impulsiveness score (β=-2.10; P=.04; 95% CI -0.94, -0.02) were predictive of changes in the patients\' treatment motivation during treatment. Moreover, patients\' baseline Generalized Anxiety Disorder-7 assessment score (β=-1.607; P=.03; 95% CI -3.08, -0.14), BIS-attentional impulsivity score (β=-2.43; P=.004; 95% CI -4.03, -0.83), and BIS-nonplanning impulsivity score (β=2.54; P=.002; 95% CI 0.98, 4.10) were predictive of changes in craving scores during treatment.
Echo-APP is a practical, accepted, and promising virtual digital psychotherapist program for patients with methamphetamine dependence. The preliminary findings lay a good foundation for further optimization of the program and the promotion of large-scale randomized controlled clinical studies for SUD.